Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
塞奥思生物科技
上海市, 上海市, 中国api.map.baidu.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
塞奥思生物科技专注于将德国RARSIG集团开发的RARS-DC-T细胞免疫治疗技术引入中国，拥有该平台全部知识产权与制备工艺。该疗法利用树突状细胞激活T淋巴球以诱导抗肿瘤免疫反应，目前处于临床前到早期临床应用阶段，尚无公开大规模临床结果。
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyDendritic cell therapy (DC-T)Immunotherapy
- Industry
- Biotech
02
Partnerships
与德国RARSIG集团深度合作；在中国寻求本地医学、研发及商业合作伙伴资源共享。
Beyond the preview
Go deeper on 塞奥思生物科技.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 塞奥思生物科技.